New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2013
15:19 EDTNVSNovartis says subpoenaed during 2012 over marketing practices
In its 2012 annual report, filed yesterday, Novartis Pharmaceuticals disclosed that during last year it received a subpoena from the United States Attorney’s Office for the Western District of Kentucky requesting the production of documents relating to marketing practices, including remuneration of healthcare providers, in connection with certain NPC products including Tekturna and its combination products. Novartis said it is cooperating with the investigation, which is civil and criminal in nature. Novartis also disclosed that in 2012 it received a civil investigative demand from the USAO for the Southern District of New York requesting information regarding its interactions with specialty pharmacies concerning certain NPC products including Gleevec and Gilenya. NPC again said it is cooperating with the civil investigation. Novartis also said that during the fourth quarter of 2012, it learned that the U.S. government is not pursuing further informed consent issues relating to clinical trials in China related to an investigation that began in 2010. The government continues to investigate marketing practices, including marketing practices concerning Zometa, Novartis said. Additionally, Novartis' Alcon Laboratories unit was notified that the USAO for the Northern District of Texas is conducting an investigation relating to the export of Alcon products to various countries subject to U.S. trade sanctions, including Iran, and received a grand jury subpoena requesting the production of documents for a period beginning in 2005 relating to this investigation, in which Alcon is cooperating.
News For NVS From The Last 14 Days
Check below for free stories on NVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
13:51 EDTNVSAlnylam COO critical of big pharma, FierceDrugDelivery reports
After Novartis (NVS) decided to end its RNAi research, Alnylam COO Barry Greene told FierceDrugDelivery that big pharma has "never been able to innovate." Greene attributes the recent sell-off in Alnylam shares to "generally bearish sentiment on Wall Street regarding biotech stocks in particular." Reference Link
11:19 EDTNVSNovartis launches new eye care products facility in Singapore, Nikkei says
Subscribe for More Information
April 15, 2014
07:35 EDTNVSAlnylam outlook not affected by Novartis decision, says JMP Securities
Subscribe for More Information
07:22 EDTNVSNovartis to Shire said to mull offers for ThromboGenics, Bloomberg says
Subscribe for More Information
06:36 EDTNVSRanbaxy inspection failures add $900M to heart drug costs, Bloomberg says
A gap in U.S. patent law has kept cheap copies of Novartis' (NVS) heart drug Diovan off the market for 18 months, which has cost U.S. consumers and insurers as much as $900M in possible savings, reported Bloomberg. Ranbaxy (RBXLY) is the only company permitted to sell a generic version of Diovan, and hasn’t been able to manufacture and market them after four factories it runs in India failed U.S. inspections. Reference Link
06:32 EDTNVSPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
14:42 EDTNVSAlnylam slips after Novartis reportedly cuts back RNAi development
Subscribe for More Information
11:48 EDTNVSNovartis significantly reducing RNAi development efforts, FierceBiotech says
Subscribe for More Information
April 9, 2014
07:09 EDTNVSReckitt Benckiser may be frontrunner for Merck unit, Bloomberg reports
Subscribe for More Information
April 8, 2014
07:22 EDTNVSCaSA-ISPE to hold a conference
21st Annual Lilfe Sciences Technology Conference is being held in Raleigh, North Carolina on April 8.
April 7, 2014
07:27 EDTNVSAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
05:32 EDTNVSNovartis Bexsero vaccine receives FDA Breakthrough Therapy designation
Novartis announced that Bexsero, Meningococcal Group B Vaccine, has received a Breakthrough Therapy designation from the FDA. Bexsero is already approved in Europe, Canada and Australia to help protect against invasive meningococcal disease caused by serogroup B. Novartis plans to file for U.S. licensure of Bexsero as early as Q2; exact timing will depend on guidance from the FDA. This is the fourth Breakthrough Therapy designation for Novartis, underscoring leadership in developing innovative therapies and vaccines. This announcement comes on the heels of a landmark decision from regulators in the UK, where the Joint Committee on Vaccination and Immunisation recommended the inclusion of Bexsero in the country's National Immunisation Programme for routine use in infants from two months of age.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use